oxiconazole (oxistat) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Oxiconazole nitrate is 2',4'-dichloro-2-imidazol-1-ylacetophenone (Z)-[0-(2,4-dichlorobenzyl)oxime], mononitrate is an imidazole derivative characterized by a broad fungistatic spectrum. In vitro oxiconazole is highly effective against many dermatophytes, including Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, and Epidermophyton floccosum. In addition, fungicidal activity of various degree was found in selected species (Aspergillus fumigatus, Cryptococcus neoformans, Candida albicans and Trichophyton mentagrophytes). Synthesis of DNA was inhibited by subinhibitory concentrations of oxiconazole in parallel to cell multiplication, whereas synthesis of RNA, protein and carbohydrate was decreased to a lesser extent. OXISTAT® (Oxiconazole nitrate) Cream and Lotion are indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum. OXISTAT® Cream is indicated for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur. Oxiconazole cream exerts no detectable systemic effect since only a negligible amount is absorbed from the skin. Once-daily use of oxiconazole cream could be valuable in patients with a history of noncompliance with multiple-daily regimens of other topical antifungal agents.   NCATS

Chemistry

  • SMILES: Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
  • InChIKey: QRJJEGAJXVEBNE-HKOYGPOVSA-N
  • Mol. Mass: 429.13
  • ALogP: 6.12
  • ChEMBL Molecules:
    oxiconazole  
    oxiconazole nitrate  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.0002 - $14.3087
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

ethanone, 1-(2,4-dichlorophenyl)-2-(1h-imidazol-1-yl)-, o-((2,4-dichlorophenyl)methyl)oxime, (z)-, mononitrate | fonx | gyno-myfungar | myfungar | oceral | oxiconazol | oxiconazole | oxiconazole mononitrate, (z)-isomer | oxiconazole nitrate | oxiconazolum | oxistat | oxizole | oxyconazole | ro 13-8996 | ro-138996 | ro-13-8996 | salongo | sgd 301-76 | sgd-301-76 | st-813 | (z)-1-(2,4-dichlorophenyl)-2-(1h-imidazol-1-yl)-o-(2,4-dichlorobenzyl) ethanone oxime nitrate

Organizations (5)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (3)


 

Tinea

Tinea Pedis (approved 1988)

Tinea Versicolor (approved 1988)

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Tinea (Phase 1)

Tinea Pedis (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue